Modeling precision genomic-based radiation dose response in rectal cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351(17), 1731–1740 (2004).
  Medline CASGoogle Scholar
• 2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 383(9927), 1490–1502 (2014).
  MedlineGoogle Scholar
• 3. Maas M, Nelemans PJ, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11(9), 835–844 (2010).
  MedlineGoogle Scholar
• 4. Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann. Surg. Oncol. 23(4), 1177–1186 (2016).
  MedlineGoogle Scholar
• 5. Appelt AL, Ploen J, Harling H et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 16(8), 919–927 (2015).
  MedlineGoogle Scholar
• 6. Deng Y, Chi P, Lan P et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm Phase III trial. J. Clin. Oncol. 34(27), 3300–3307 (2016).
  Medline CASGoogle Scholar
• 7. Overgaard M, Overgaard J, Sell A. Dose–response relationship for radiation therapy of recurrent, residual, and primarily inoperable colorectal cancer. Radiother. Oncol. 1(3), 217–225 (1984).
  Medline CASGoogle Scholar
• 8. Chan AK, Wong AO, Langevin J et al. Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a Phase II dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 48(3), 843–856 (2000).
  Medline CASGoogle Scholar
• 9. Habr-Gama A, Perez RO, Nadalin W et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann. Surg. 240(4), 711–717 (2004).
  MedlineGoogle Scholar
• 10. Renehan AG, Malcomson L, Emsley R et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 17(2), 174–183 (2016).
  MedlineGoogle Scholar
• 11. van der Valk MJM, Hilling DE, Bastiaannet E et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139), 2537–2545 (2018).
  MedlineGoogle Scholar
• 12. Bettoni F, Masotti C, Habr-Gama A et al. Intratumoral genetic heterogeneity in rectal cancer: are single biopsies representative of the entirety of the tumor? Ann. Surg. 265(1), e4–e6 (2017).
  MedlineGoogle Scholar
• 13. McCawley N, Clancy C, O'Neill BD, Deasy J, McNamara DA, Burke JP. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis. Colon Rectum 59(12), 1200–1208 (2016).
  MedlineGoogle Scholar
• 14. Sagaert X, Vanstapel A, Verbeek S. Tumor heterogeneity in colorectal cancer: what do we know so far? Pathobiology 85(1–2), 72–84 (2018).
  Medline CASGoogle Scholar
• 15. Punt CJA, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 14, 235 (2016).
  MedlineGoogle Scholar
• 16. National Comprehensive Cancer Network. NCCN guideline. Rectal cancer (2018). www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
  Google Scholar
• 17. Torres-Roca JF, Eschrich S, Zhao H et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 65(16), 7169–7176 (2005).
  Medline CASGoogle Scholar
• 18. Eschrich SA, Pramana J, Zhang H et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 489–496 (2009). • Demonstrates radiation sensitivity index correlated with pathological response in rectal cancer.
  Medline CASGoogle Scholar
• 19. Eschrich S, Zhang H, Zhao H et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 497–505 (2009).
  Medline CASGoogle Scholar
• 20. Eschrich SA, Fulp WJ, Pawitan Y et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin. Cancer Res. 18(18), 5134–5143 (2012).
  MedlineGoogle Scholar
• 21. Ahmed KA, Fulp WJ, Berglund AE et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int. J. Radiat. Oncol. Biol. Phys. 92(4), 837–842 (2015).
  MedlineGoogle Scholar
• 22. Strom T, Hoffe SE, Fulp W et al. Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother. Oncol. 117(1), 159–164 (2015).
  MedlineGoogle Scholar
• 23. Ahmed KA, Chinnaiyan P, Fulp WJ, Eschrich S, Torres-Roca JF, Caudell JJ. The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget 6(33), 34414–34422 (2015).
  MedlineGoogle Scholar
• 24. Torres-Roca JF, Fulp WJ, Caudell JJ et al. Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 93(3), 631–638 (2015).
  MedlineGoogle Scholar
• 25. Ahmed KA, Caudell JJ, El-Haddad G et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 95(5), 1399–1404 (2016).
  MedlineGoogle Scholar
• 26. Ahmed KA, Berglund AE, Welsh EA et al. The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neuro Oncol. 19(8), 1145–1146 (2017).
  MedlineGoogle Scholar
• 27. Ahmed KA, Scott JG, Arrington JA et al. Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose. J. Thorac. Oncol. 13(8), 1121–1127 (2018).
  Medline CASGoogle Scholar
• 28. Scott JG, Berglund A, Schell MJ et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 18(2), 202–211 (2017). •• Explores the concept of genomic-based radiation dosing.
  MedlineGoogle Scholar
• 29. Torres-Roca JF. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy. Per. Med. 9(5), 547–557 (2012).
  CASGoogle Scholar
• 30. Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother. Oncol. 113(1), 1–9 (2014).
  MedlineGoogle Scholar
• 31. Hall MD, Schultheiss TE, Smith DD, Fakih MG, Wong JY, Chen YJ. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol. 55(12), 1392–1399 (2016).
  Medline CASGoogle Scholar
• 32. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int. J. Radiat. Oncol. Biol. Phys. 84(4), 949–954 (2012).
  MedlineGoogle Scholar
• 33. Martens MH, Maas M, Heijnen LA et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J. Natl Cancer Inst. 108(12), djw171 (2016).
  MedlineGoogle Scholar